IPO Porto Research Center
IPO Porto is a member of the Organization of European Cancer Institutes (OECI) and is accredited by OECI as a Comprehensive Cancer Center (Porto Comprehensive Cancer Center; Porto.CCC) in collaboration with Instituto de Investigação e Inovação em Saúde (i3S).
CI-IPOP has the mission to coordinate and implement the research activity of IPO Porto. It is a founding member of the Associated Laboratory Health Research Network (RISE) in which it coordinates the Thematic line 2 (TL2)- “CLINICAL AND TRANSLATIONAL RESEARCH IN ONCOLOGY”
CI-IPOP is an FCT R&D unit since 2004, rated as Excellent in the last international evaluation (2019).
CI-IPOP comprises 5 translational research groups (Cancer Biology & Epigenetics; Cancer Genetics; Experimental Pathology & Therapeutics; Medical Physics, Radiobiology & Radiation Protection; and Molecular Oncology & Viral Pathology), two clinical groups (Precancerous Lesions and Early Cancer Management and Clinical Oncology) and two groups devoted to meet the growing needs on epidemiology of cancer, patient outcome and quality of life, as well as value-based healthcare and sustainability (Cancer Epidemiology and Management, Outcomes Research & Economics in Healthcare); along with a Clinical Research Unit (with 145 active clinical trials ongoing), which includes an Early phase clinical trials Unit dedicated to investigator-initiated trials, and the recently created Oncology Nursing Research Unit. CI-IPOP activity is supported by IPO Porto’s Biobank.
CI-IPOP long-term objective is to understand the pathobiologic mechanisms of tumorigenesis and enable Precision Oncology. Patient-centred translational and clinical research is focused on:
- Development of new diagnostic, prognostic and monitoring biomarkers using liquid biopsies;
- Identification of novel therapeutic targets to be tested in early phase clinical trials;
- Improvement of bioimaging, bioinformatics, and outcome assessment tools;
- Support of the Precision Oncology Program at IPO Porto (POP-IPOP).
CI-IPOP includes more than 200 members of which 70 hold a PhD and 103 an MSc. In addition to IPO Porto staff, that includes 73 MDs, 39 health technicians, 33 researchers and 17 PhD students, 35 members are supported by fellowships (28 PhD students and 7 research assistants) and 21 are MSc students.
Director: Prof. Carmen Jerónimo, PhD
Vice-directors: Prof. Mário Dinis Ribeiro, MD, PhD, and Prof. Rui Medeiros, PhD
The Research Center facilities are distributed across eight different areas in IPO Porto. This includes three translational research laboratories (1, 2 and 3) and five non-translational research laboratories (4, 5, 6 7 and 8).
In 2021, CI-IPOP members published a total of 280 peer-reviewed scientific articles, and 232 of those were published in journals with impact factor. From all the publications, 169 had at least one category in Q1 from Scimago classification. Among these, 51 were on the “Oncology” category, 37 in “medicine” and 17 were in the “cancer research” category. Of those, the mean impact factor (IF) was 6.4 and the Sum of impact factors was 1467.157. Moreover, 82 articles were published in journals with IF between 5 and 10, with 31 publications with IF above 10.
INTERNATIONAL EVALUATION BY FCT (2019)
CI-IPOP was rated as EXCELLENT for the period 2013-2017 and activity plan for 2020-2023 following an international evaluation performed by the panel HEALTH SCIENCES – Clinical and Translational Research organized by FCT. The resulting FCT basic and strategic funding (UIDB-00776-2020 and UIDP-00776-2020) amounts to a total of 1,242,000€ for the period 2020-2023, which includes new PhD researcher contracts. Moreover, the international evaluation awarded eight PhD fellowships to CI-IPOP directly funded by FCT for the same period.